首页 > 市场调查报告书 > 製药

生物製剂

mTOR抑制剂的全球市场:药物类型，适应症，给药途径，流通管道，各地区 - 规模，占有率，展望，机会分析(2022年～2030年)

市场调查报告书

商品编码

1086012

mTOR抑制剂的全球市场:药物类型，适应症，给药途径，流通管道，各地区 - 规模，占有率，展望，机会分析(2022年～2030年)

mTOR Inhibitors Market, by Drug Type, By Indication, by Route of Administration, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

出版日期: 2022年05月16日 | 出版商:

Coherent Market Insights | 英文 175 Pages | 商品交期: 2-3个工作天内

价格

简介目录

全球mTOR抑制剂市场，来自法规机关的产品核可的增加预计促进在预测期间内的成长。

本报告提供全球mTOR抑制剂市场相关调查，市场动态，COVID-19影响，各市场区隔、地区的市场分析，竞争情形，主要企业的简介等资讯。

企业简介
- Novartis AG
- Hikma Pharmaceuticals PLC.
- Par Pharmaceutical
- Teva Pharmaceutical Industries Ltd.
- Reddy's Laboratories Ltd.
- Zydus Cadilla
- Pfizer, Inc.
- Biocon
- Alkem Laboratories Ltd.
- Accord Healthcare Inc.
- Gland Pharma Ltd.
- Apotex Inc.
- Glenmark Pharmaceuticals Ltd.
分析师的见解

第11章 Section

简介目录

Product Code: CMI5019

Mammalian target of rapamycin (mTOR) is a protein kinase, which regulates growth factors that stimulate cell growth and angiogenesis. Mammalian target of rapamycin (mTOR) inibitors controls the cell division, and controls the growth of cancer cells from growing and prevent the growth of new blood vessels that tumors need to grow. Mammalian target of rapamycin (mTOR) inhibitors are used in the treatment of renal cancer and it is being studied for use in other types of cancers. mTOR are indicated for the treatment of breast cancer, lymphangioleiomyomatosis, neuroendocrine carcinoma, organ transplant, pancreatic cancer, renal cell carcinoma, tuberous sclerosis complex and others. Mammalian target of rapamycin (mTOR), drugs are- Everolimus, Temsirolimus, and Sirolimus. Mammalian target of rapamycin (mTOR) has common and serious class side effects of mTOR inhibitors include non-infectious pneumonitis, metabolic disorders and mucosal toxicity.

Market Dynamics

Increasing product approvals from regulatory bodies is expected to drive the growth of global mTOR Inhibitors market during the forecast period. For instance, in June 2021, Breckenridge Pharmaceutical, Inc., a subsidiary of Towa Pharmaceutical announced that the U.S. Food and Drug Administration has granted final approval of its Abbreviated New Drug Application for Everolimus Tablets (generic for Zortress). Everolimus tablets will be in strength of 0.25mg, 0.5mg, and 0.75mg.

Increasing number of prevalence of renal cell carcinoma is expected to drive the growth of global mTOR inhibitors market. For instance, according to an article published by the U.S. Department of Health and Human Services, published in 2018, there were an estimated 582,727 people living with kidney and renal pelvis cancer in the U.S.

Key features of the study:

This report provides an in-depth analysis of global mTOR inhibitors market, provides market size (US$ Million), and compound annual growth rate (CAGR %) for the forecast period (2022-2030), considering 2021 as the base year

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market

This study also provides key insights about market drivers, restraints, opportunities, new drug launches or approval, regional outlook, and competitive strategies adopted by the leading players

It profiles leading players in the global mTOR inhibitors market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans.

Key companies covered as a part of this study include Novartis AG, Hikma Pharmaceuticals PLC., Par Pharmaceutical, Teva Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., Zydus Cadilla, Pfizer, Inc., Biocon, Alkem Laboratories Ltd., Accord Healthcare Inc., Gland Pharma Ltd., Apotex Inc., and Glenmark Pharmaceuticals Ltd.

Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launch, technology up-gradation, market expansion, and marketing tactics

The global mTOR inhibitors market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts.

Stakeholders would have ease in decision making through various strategy matrices used in analyzing the global mTOR inhibitors

Detailed Segmentation:

Global mTOR Inhibitors Market, By Drug Type:
- Everolimus
- Temsirolimus
- Sirolimus
Global mTOR Inhibitors Market, By Indication:
- Oncology
- Immunosuppressant
- Organ Transplantation
- Others
Global mTOR Inhibitors Market, By Route of Administration:
- Oral
- Intravenous
Global mTOR Inhibitors Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Global mTOR Inhibitors Market, By Region:
- North America
  - By Country:
- U.S.
- Canada
- Latin America
  - By Country:
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
  - By Country:
- U.K.
- Germany
- Italy
- Spain
- France
- Russia
- Rest of Europe
- Asia Pacific
  - By Country:
- Australia
- India
- China
- Japan
- ASEAN
- South Korea
- Rest of Asia Pacific
- Middle East
  - By Country:
- GCC
- Israel
- Rest of Middle East
- Africa
  - By Country/Region:
- South Africa
- Central Africa
- North Africa
Company Profiles
- Novartis AG*
  - Company Overview
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Strategies
- Hikma Pharmaceuticals PLC.
- Par Pharmaceutical
- Teva Pharmaceutical Industries Ltd.
- Reddy's Laboratories Ltd.
- Zydus Cadilla
- Pfizer, Inc.
- Biocon
- Alkem Laboratories Ltd.
- Accord Healthcare Inc.
- Gland Pharma Ltd.
- Apotex Inc.
- Glenmark Pharmaceuticals Ltd.

"" marked represents similar segmentation in other categories in the respective section.*

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Overview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snippet, By Drug Type
- Market Snippet, By Indication
- Market Snippet, By Route of Administration
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Impact Analysis
Key Development
PEST Analysis
Regulatory Scenario
Pipeline Analysis
New Product Launch/ Approval
Epidemiology
Market Trends

4. Global mTOR Inhibitors Market - Impact of Coronavirus (Covid-19) Pandemic

Economic Impact
COVID-19 Epidemiology
Government Initiatives to Combat COVID-19

5. Global mTOR Inhibitors Market, By Drug Type, 2017 - 2030 (US$ Million)

Introduction
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 - 2030
- Segment Trends
Everolimus
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Million)
Temsirolimus
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Million)
Sirolimus
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Million)

6. Global mTOR Inhibitors Market, By Indication, 2017 - 2030 (US$ Million)

Introduction
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 - 2030
- Segment Trends
Oncology
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Million)
Immunosuppressant
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Million)
Organ Transplantation
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Million)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Million)

7. Global mTOR Inhibitors Market, By Route of Administration, 2017 - 2030 (US$ Million)

Introduction
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 - 2030
- Segment Trends
Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Million)
Intravenous
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Million)

8. Global mTOR Inhibitors Market, By Distribution Channel, 2017 - 2030 (US$ Million)

Introduction
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 - 2030
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Million)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Million)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030 (US$ Million)

9. Global mTOR Inhibitors Market, By Region, 2017 - 2028 (US$ Million)

Introduction
- Market Share Analysis, By Region, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, For Regions, 2017 - 2030
- Regional Trends
North America
- Market Size and Forecast, By Drug, 2017 - 2030 (US$ Mn)
- Market Size and Forecast, By Indication, 2017 - 2030 (US$ Mn)
- Market Size and Forecast, By Route of Administration, 2017 - 2030 (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 - 2030 (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2030 (US$ Mn)
U.S.
Canada
Latin America
- Market Size and Forecast, By Drug, 2017 - 2030 (US$ Mn)
- Market Size and Forecast, By Indication, 2017 - 2030 (US$ Mn)
- Market Size and Forecast, By Route of Administration, 2017 - 2030 (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 - 2030 (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2030 (US$ Mn)
Brazil
Mexico
Argentina
Rest of Latin America
Europe
- Market Size and Forecast, By Drug, 2017 - 2030 (US$ Mn)
- Market Size and Forecast, By Indication, 2017 - 2030 (US$ Mn)
- Market Size and Forecast, By Route of Administration, 2017 - 2030 (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 - 2030 (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2030 (US$ Mn)
Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe
Asia Pacific
- Market Size and Forecast, By Drug, 2017 - 2030 (US$ Mn)
- Market Size and Forecast, By Indication, 2017 - 2030 (US$ Mn)
- Market Size and Forecast, By Route of Administration, 2017 - 2030 (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 - 2030 (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2030 (US$ Mn)
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
- Market Size and Forecast, By Drug, 2017 - 2030 (US$ Mn)
- Market Size and Forecast, By Indication, 2017 - 2030 (US$ Mn)
- Market Size and Forecast, By Route of Administration, 2017 - 2030 (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 - 2030 (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2030 (US$ Mn)
GCC
Israel
Rest of Middle East
Africa
- Market Size and Forecast, By Drug, 2017 - 2030 (US$ Mn)
- Market Size and Forecast, By Indication, 2017 - 2030 (US$ Mn)
- Market Size and Forecast, By Route of Administration, 2017 - 2030 (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 - 2030 (US$ Mn)
- Market Size and Forecast, By Country/Region, 2017 - 2030 (US$ Mn)
South Africa
Central Africa
North Africa

10. Competitive Landscape

Company Profiles
- Novartis AG
Company Overview
Product Portfolio
Financial Performance
Recent Developments/Updates
Strategies
- Hikma Pharmaceuticals PLC.
Company Overview
Product Portfolio
Financial Performance
Recent Developments/Updates
Strategies
- Par Pharmaceutical
Company Overview
Product Portfolio
Financial Performance
Recent Developments/Updates
Strategies
- Teva Pharmaceutical Industries Ltd.
Company Overview
Product Portfolio
Financial Performance
Recent Developments/Updates
Strategies
- Reddy's Laboratories Ltd.
Company Overview
Product Portfolio
Financial Performance
Recent Developments/Updates
Strategies
- Zydus Cadilla
Company Overview
Product Portfolio
Financial Performance
Recent Developments/Updates
Strategies
- Pfizer, Inc.
Company Overview
Product Portfolio
Financial Performance
Recent Developments/Updates
Strategies
- Biocon
Company Overview
Product Portfolio
Financial Performance
Recent Developments/Updates
Strategies
- Alkem Laboratories Ltd.
Company Overview
Product Portfolio
Financial Performance
Recent Developments/Updates
Strategies
- Accord Healthcare Inc.
Company Overview
Product Portfolio
Financial Performance
Recent Developments/Updates
Strategies
- Gland Pharma Ltd.
Company Overview
Product Portfolio
Financial Performance
Recent Developments/Updates
Strategies
- Apotex Inc.
Company Overview
Product Portfolio
Financial Performance
Recent Developments/Updates
Strategies
- Glenmark Pharmaceuticals Ltd.
Company Overview
Product Portfolio
Financial Performance
Recent Developments/Updates
Strategies
Analyst Views

11. Section

References
Research Methodology
About Us and Sales Contact

02-2729-4219

+886-2-2729-4219

License/价格

mTOR抑制剂的全球市场:药物类型，适应症，给药途径，流通管道，各地区 - 规模，占有率，展望，机会分析(2022年～2030年)

mTOR Inhibitors Market, by Drug Type, By Indication, by Route of Administration, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

目录

第1章调查目的、前提条件

第2章市场概要

第3章市场动态，法规，及趋势分析

第4章全球mTOR抑制剂市场-冠状病毒(COVID-19)大流行的影响

第5章全球mTOR抑制剂市场:各药物类型

第6章全球mTOR抑制剂市场:各适应症

第7章全球mTOR抑制剂市场:各给药途径

第8章全球mTOR抑制剂市场:各流通管道

第9章全球mTOR抑制剂市场:各地区

第10章竞争情形